Protect Your Bank Account Before It’s Too Late

For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …

Stop right now and do these 3 things to protect yourself

Brian Birchler Biography and Net Worth

EVP of Ionis Pharmaceuticals

Mr. Birchler is Ionis’ executive vice president, corporate and development operations. In this role, he provides executive leadership for several functions, including clinical operations and data management, global project and portfolio management, biometrics and clinical supplies. He also provides management support for development and research budgets and product launch excellence. Mr. Birchler is a member of Ionis' executive leadership team.

Mr. Birchler has over 30 years of experience in the biopharmaceutical and medical device industries and broad knowledge of the drug development process from concept through launch. Since joining Ionis in 1995 he has held positions of increasing responsibility in development, clinical research and development chemistry. Before Ionis, he held positions at CIBA Vision Corp. and Burroughs Wellcome Pharmaceuticals. Mr. Birchler has a bachelor’s degree in industrial technology from the University of Wisconsin-Stout.

What is Brian Birchler's net worth?: The estimated net worth of Brian Birchler is at least $1.52 million as of April 18th, 2023. Mr. Birchler owns 36,528 shares of Ionis Pharmaceuticals stock worth more than $1,519,200 as of April 27th. This net worth approximation does not reflect any other assets that Mr. Birchler may own. Learn More about Brian Birchler's net worth.
How do I contact Brian Birchler?: The corporate mailing address for Mr. Birchler and other Ionis Pharmaceuticals executives is 2855 GAZELLE COURT, CARLSBAD CA, 92010. Ionis Pharmaceuticals can also be reached via phone at (760) 931-9200 and via email at [email protected]. Learn More on Brian Birchler's contact information.
Has Brian Birchler been buying or selling shares of Ionis Pharmaceuticals?: Brian Birchler has not been actively trading shares of Ionis Pharmaceuticals during the last ninety days. Most recently, Brian Birchler sold 672 shares of the business's stock in a transaction on Tuesday, April 18th. The shares were sold at an average price of $36.50, for a transaction totalling $24,528.00. Following the completion of the sale, the executive vice president now directly owns 36,528 shares of the company's stock, valued at $1,333,272. Learn More on Brian Birchler's trading history.
Who are Ionis Pharmaceuticals' active insiders?: Ionis Pharmaceuticals' insider roster includes C. Bennett (EVP), Spencer Berthelsen (Director), Brian Birchler (EVP), Onaiza Cadoret-Manier (EVP), Breaux Castleman (Director), Stanley Crooke (Chairman), Allene Diaz (Director), Richard Geary (EVP), Elizabeth Hougen (CFO), Joseph Klein, III (Director), Brett Monia (CEO), Frederick Muto (Director), Patrick O'Neil (EVP), B. Parshall, Esq. (Director), Eugene Schneider (EVP), and Eric Swayze (EVP). Learn More on Ionis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ionis Pharmaceuticals?: During the last year, insiders at the sold shares 28 times. They sold a total of 291,805 shares worth more than $14,352,782.01. The most recent insider tranaction occured on April, 16th when EVP Joseph Baroldi sold 4,006 shares worth more than $166,649.60. Insiders at Ionis Pharmaceuticals own 2.7% of the company. Learn More about insider trades at Ionis Pharmaceuticals.
Information on this page was last updated on 4/16/2024.

Brian Birchler Insider Trading History at Ionis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/18/2023	Sell	672	$36.50	$24,528.00	36,528

Brian Birchler Buying and Selling Activity at Ionis Pharmaceuticals

Ionis Pharmaceuticals Company Overview

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Today's Range

Now: $41.59

$41.36

$42.28

50 Day Range

MA: $43.33

$40.68

$47.41

2 Week Range

Now: $41.59

$34.32

$54.44

Volume

556,043 shs

Average Volume

856,032 shs

Market Capitalization

$6.06 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39